Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.
Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL
Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL
What Analyst Projections for Key Metrics Reveal About Charles River (CRL) Q4 Earnings
Besides Wall Street's top-and-bottom-line estimates for Charles River (CRL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Here's How Charles River Stock Is Placed Ahead of Q4 Earnings
CRL heads into Q4 earnings with collaborations and strength in RMS and Manufacturing, even as DSA headwinds weigh on revenue expectations.
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
What Makes Charles River (CRL) a New Buy Stock
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
Charles River gains from strong RMS demand, strategic partnerships and solid finances but faces macro and competitive pressures in 2025.
